CFDE Data Portal | Search DOCK8-AS1

	Label	Description
	DOCK8-AS1 Gene (Entity type)	ENSG00000183784 - DOCK8 antisense RNA 1
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE135030 3 V 10 FLUDARABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 4 V 2 CHLOROQUINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 11 V 9 CRIZOTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 7 V 5 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS

DOCK8-AS1

ENSG00000183784 - DOCK8 antisense RNA 1

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP

A Gene Set from LINCS

GSE135030 3 V 10 FLUDARABINE HUMAN UP

A Gene Set from LINCS

GSE159678 4 V 2 CHLOROQUINE HUMAN UP

A Gene Set from LINCS

GSE238213 dopamine 2 v 0 human up

A Gene Set from LINCS

GSE239844 11 V 9 CRIZOTINIB HUMAN UP

A Gene Set from LINCS

GSE120612 7 V 5 ETOPOSIDE HUMAN UP

A Gene Set from LINCS

GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.